There are indeed several therapeutic strategies, and approved and underdeveloped agents targeting CFTR channels have been attempted or translated into new treatments for mucus obstructive pulmonary diseases that share the same pathophysiology with CF, such as COPD, among which antioxidant ROS scavenger, mucus rehydration and mucolytic therapy, CFTR stimulator (phosphodiesterase (PDE) inhibitor), and CFTR potentiators gain the most interest in testing for COPD treatments (Figure 3). Here, ALDH7A1 is linked to chronic obstructive pulmonary disease.